Management of lipid variables in primary cardiovascular prevention: A position paper from the Heart, Vessels and Metabolism Group of the French Society of Cardiology - 01/06/24
, Eric Bruckert b, Victor Aboyans c, Saïd Bekka d, Franck Boccara e, Barthelemy Bourdon Baron Munoz f, Joseph Emmerich g, Michel Farnier h, Antonio Gallo b, Gilles Lemesle i, François Paillard j, François Schiele k, Serge Kownator lfor the
Heart, Vessels and Metabolism Group of the French Society of Cardiology
Graphical abstract |
Highlights |
• | Primary prevention is complex and needs the consent of a patient without disease. |
• | Primary prevention requires adoption of new behaviours or taking medications. |
• | Reduction of LDL-C is an excellent target for reducing risk of a cardiovascular event. |
• | The patient must be convinced that LDL-C is a key marker of cardiovascular risk. |
Abstract |
Low-density lipoprotein cholesterol has been established as a powerful cardiovascular risk factor; its reduction provides a clinical benefit in primary cardiovascular prevention, irrespective of the characteristics of the patients treated. It is useful to tailor low-density lipoprotein cholesterol targets according to the magnitude of cardiovascular risk (low, high or very high) in order to reduce the cardiovascular risk as fully as possible. In order to provide a uniform approach, it is necessary to propose recommendations for good practice, defining strategies for reducing low-density lipoprotein cholesterol. It is also necessary to know their merits, to analyse their practical limits and to propose adaptations, taking into account limitations and national specifics. This position paper aims to analyse the contribution and limits, as well as the adaptation to French practice, of 2019 and 2021 European Society of Cardiology recommendations for the management of lipid variables and cardiovascular prevention.
Le texte complet de cet article est disponible en PDF.Keywords : Lipids, Low-density lipoprotein cholesterol, Cardiovascular primary prevention
Plan
| ☆ | Tweet: A French position paper to analyse contribution and limits of ESC guidelines on primary prevention and its adaptation to clinical practice. |
Vol 117 - N° 5
P. 358-378 - mai 2024 Retour au numéro
Article précédent
- Acute coronary syndrome in patients treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants: Proposed management algorithm for the first 48 hours
- Alexandre Salaun, Emmanuel de Maistre, Marlène Daller, Chan Sombrun, Frédéric Chagué, Florence Bichat, Luc Rochette, Nicolas Danchin, Laurent Fauchier, Marianne Zeller, Yves Cottin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?